We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed pretty well, leading to a post-earnings jump ...

Novo Nordisk is by far the leader in the GLP-1 drug market. The company's pipeline in this area is also very deep. The Danish drugmaker is also looking to diversify its lineup. Novo Nordisk's work ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...

Novo Nordisk (NVO) remains a dominant force in diabetes and obesity treatments, yet the stock is currently trading below its fair value. Despite a recent decline following disappointing trial results ...

Novo Nordisk (NVO) remains a dominant force in diabetes and obesity treatments, yet the stock is currently trading below its fair value. Despite a recent decline following disappointing trial ...

multi-product API facility in Kalundborg, Denmark. In addition to the expansion in Denmark, Novo Nordisk will increase its exposure in countries such as Brazil, France, China and, of course ...

Novo Nordisk A/S's recent 44% decline combined with impressive Q4 2024 and fiscal 2024 results with strong sales and profit growth raise the question if the company is a “Buy” again.

Novo Nordisk's profit of DKK28.23 billion also topped estimates. Wegovy sales soared 107% at constant exchange rates to DKK19.87 billion, just below estimates. Ozempic sales rose 12% to DKK33.85 ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...